IL-2-expressing cell therapies (Intrexon/Ziopharm)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameIL-2-expressing cell therapies (Intrexon/Ziopharm)
Drug Alias NameFOXP3-expressing genetically engineered regulatory T-cells (Intrexon/Ziopharm)IL-2-expressing cell therapies (Precigen/Ziopharm)
ClassificationCell and gene therapy > Cell therapy
Mechanisms of ActionForkhead box protein P3 stimulantsInterleukin-2 modulators
TargetsForkhead box protein P3Interleukin-2
Therapy Area/IndicationsGraft vs Host Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesPrecigen Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAlaunos Therapeutics IncPrecigen Inc
Active IndicationsN/A
Inactive IndicationsGraft vs Host Disease

Other Information

ATC CodeN/A
Related LinksN/A